Myelodysplastic syndrome in a patient with adult T‐cell leukaemia

• Published in: British journal of haematology 1999-09, Vol.106 (3), p.702-705
• Main Authors: Kawabata, Hisashi, Utsunomiya, Atae, Hanada, Shuichi, Makino, Torahiko, Takatsuka, Yoshifusa, Takeuchi, Shogo, Suzuki, Shinsuke, Suzumiya, Junji, Ohshima, Kouichi, Horiike, Shigeo
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; adult T‐cell leukaemia; Antineoplastic Agents - adverse effects; Biological and medical sciences; Blotting, Southern; chromosome abnormality; DNA, Viral - isolation & purification; Drug toxicity and drugs side effects treatment; Fatal Outcome; Female; Hematology; Humans; Karyotyping; Leukemia-Lymphoma, Adult T-Cell - complications; Leukemia-Lymphoma, Adult T-Cell - drug therapy; Male; Medical sciences; Middle Aged; Myelodysplastic Syndromes - chemically induced; Pharmacology. Drug treatments; therapy‐related myelodysplastic syndrome; Toxicity: blood
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1046/j.1365-2141.1999.01610.x

A 53‐year‐old female who developed myelodysplastic syndrome (MDS) after chemotherapy for adult T‐cell leukaemia (ATL) is described. The latent period of therapy‐related MDS (t‐MDS) from the time of diagnosis of ATL was approximately 35 months. Cytogenetic analysis of the bone marrow cells at the time of diagnosis of t‐MDS revealed a clonal abnormality; 46,XX,add(7)(p13), der(17)t(3;17)(p11;p13). Although monoclonal integration of human T lymphotropic virus type I (HTLV‐I) proviral DNA was detected in the peripheral blood lymphocytes at ATL diagnosis, bone marrow cells at t‐MDS diagnosis did not show monoclonal integration of HTLV‐I. To our knowledge, this is the first report of t‐MDS associated with ATL.